Retinoblastoma (Rb) is a primary pediatric ocular cancer and one of the first tumors to have a known genetic etiology.
1-4 Most germline and sporadic forms of Rb develop in response to biallelic mutations in
RB1 (phenotype OMIM 180200 and gene/locus OMIM 614041), the first molecularly defined tumor suppressor gene.
2,4,5 The elucidation of this gene and study of Rb provided a firm foundation for the field of cancer genetics. In addition to having
RB1 mutations, Rb tumors analyzed after enucleation demonstrate recurrent chromosomal copy number variation (eg, regions of chromosomal gains and losses).
6 These chromosomal changes underlie many human cancers
7 and are frequent secondary genomic events during Rb tumorigenesis and contribute to disease progression.
8,9 Yet, it has not been possible to define the effects of these chromosomal changes on treatment response and the disease course in Rb due to lack of access to tumor DNA. This lack of access is because, unlike many cancers, biopsy of Rb is contraindicated because of risk of tumor seeding outside the eye, possibly leading to orbital relapse.
10-16